• Company
• Oral contraceptive market expands
• by Whang, byung-woo Dec 23, 2024 04:19pm

• Company
• Multidisciplinary approach required for urothelial carcinoma
• by Whang, byung-woo Dec 23, 2024 05:50am

• Policy
• Original 'Otezla' withdraws, whereas 5 generics get listed
• by Lee, Tak-Sun Dec 23, 2024 05:50am

• Policy
• New drug approval fees to increase next year
• by Lee, Hye-Kyung Dec 23, 2024 05:50am

• Company
• Takeda's Firazyr reimbursable up to four doses per Rx
• by Whang, byung-woo Dec 23, 2024 05:49am

• Policy
• Daewoong to replace Astellas Irribow’s gap
• by Lee, Hye-Kyung Dec 23, 2024 05:49am

• Policy
• Price of Pulmicort raised again upon request
• by Lee, Tak-Sun Dec 23, 2024 05:49am

• Policy
• Gilead starts trial for its autoimmune disease drug in KOR
• by Lee, Hye-Kyung Dec 20, 2024 05:47am

• Policy
• Keytruda’s reimb for gastric cancer will be redeliberated
• by Lee, Tak-Sun Dec 20, 2024 05:46am

• Company
• LG Chem wins Zemiglo patent dispute
• by Kim, Jin-Gu Dec 20, 2024 05:46am